BioXcel Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $757.50K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | Before market open | – | $-0.54 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 27, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | $98.00K | $-2.18 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | $120.00K | $-2.45 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | Before market open | – | $-1.50 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | During market hours | – | $-3.57 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | $214.00K | $-0.32 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | $1.10M | $-0.21 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 12, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | Before market open | – | – | – |
Press releases
Announcements BioXcel Therapeutics filed with the SEC
First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
Results of operations · EX-99.1 to Form 8-K
BioXcel Therapeutics Reports Third Quarter 2025
Results of operations · EX-99.1 to Form 8-K
BXCL501 (Sublingual Dexmedetomidine) for Treatment of Agitation Associated With Bipolar Disorder or Schizophrenia
Other events · EX-99.1 to Form 8-K
Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
in Canaccord Genuity 45th Annual Growth Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
BioXcel Therapeutics | 555 Long Wharf Drive, 12th Floor | New Haven, CT 06511 | www.bioxceltherapeutics.com
Other events · EX-99.1 to Form 8-K
BioXcel Therapeutics Reports First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
BioXcel Therapeutics Reports Financial Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
BioXcel Therapeutics Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales
Results of operations · EX-99.1 to Form 8-K
BioXcel Therapeutics Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
® BioXcel Therapeutics | 555 Long Wharf Drive, 12th Floor | New Haven, CT 06511 | bioxceltherapeutics.com NASDAQ: BTAI April 2024 AI - Driven Transformative Medicines in Neuroscience
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
® Acute Treatment of Agitation Associated with Alzheimer’s Dementia (AAD) ® 1 ® TRANQUILITY Program April 10, 2024
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Results for the Fourth Quarter and Full Year 2023
Results of operations · EX-99.1 to Form 8-K
BioXcel Therapeutics Aligns with FDA Recommendation
Results of operations · EX-99.1 to Form 8-K
BioXcel Therapeutics Reports Positive Overall
Regulation FD disclosure · EX-99.1 to Form 8-K
Astria Therapeutics October 2023 1 Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
BioXcel Therapeutics Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
BioXcel Therapeutics Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
BioXcel Therapeutics Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
BioXcel Therapeutics | 555 Long Wharf Drive, 12th Floor | New Haven, CT 06511 | www.bioxceltherapeutics.com
Other events · EX-99.1 to Form 8-K
BioXcel Therapeutics Reports Third Quarter 2022
Results of operations · EX-99.1 to Form 8-K
BioXcel Therapeutics | 555 Long Wharf Drive, 12th Floor | New Haven, CT 06511 | www.bioxceltherapeutics.com
Other events · EX-99.1 to Form 8-K
BioXcel Therapeutics Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
BioXcel Therapeutics Reports First Quarter 2022
Results of operations · EX-99.1 to Form 8-K
BioXcel Therapeutics Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
Results of operations · EX-99.1 to Form 8-K